메르켈세포암(MCC) : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 리포트(주요 32 시장), 2025-2035년

Global Merkel Cell Carcinoma (MCC) Market Outlook

Thelansis's "Global Merkel Cell Carcinoma (MCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Merkel Cell Carcinoma treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Merkel Cell Carcinoma (MCC) Overview

Merkel Cell Carcinoma is an aggressive neuroendocrine skin malignancy arising from mechanoreceptor cells, strongly linked to Merkel cell polyomavirus and UV-induced immunosuppression. It typically presents as a firm, painless, flesh-colored or violaceous nodule on sun-exposed skin in elderly or immunocompromised patients. Diagnosis involves excisional biopsy with CK20 and synaptophysin immunostaining; nodal involvement and distant metastasis define severity. Surgery with sentinel lymph node biopsy forms the primary approach, with adjuvant radiotherapy for locoregional control. PD-1/PD-L1 checkpoint inhibitors are first-line for advanced disease. Surveillance imaging monitors recurrence. Prognosis worsens significantly with metastasis; early detection and multidisciplinary care are essential.

Key Highlights

• In Germany, diagnosed Merkel Cell Carcinoma (MCC) cases are projected to increase from 315 in 2025 to 335 by 2035.
• MCC is a rare and aggressive neuroendocrine skin cancer associated with a high risk of recurrence and metastasis.
• Despite advances in immunotherapy, patients with advanced or treatment-refractory disease continue to face poor clinical outcomes.
• Significant unmet need remains for therapies capable of improving long-term survival and durable disease control.

Market Overview

• The Germany MCC market is projected to grow from $180M in 2025 to $360M by 2035.
• Market growth is driven by:
• Increasing adoption of immune checkpoint inhibitors
• Ongoing development of novel immuno-oncology therapies
• Future growth will depend on therapies capable of delivering durable responses and overcoming treatment resistance.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Merck Sharp & Dohme LLC
• Incyte Corporation
• Fujifilm Pharmaceuticals U.S.A., Inc.
• Replimune, Inc.
• Phio Pharmaceuticals Inc.
• Sotio Biotech Inc.
• Kupando GmbH
• AstraZeneca
• Checkpoint Therapeutics, Inc.
• ImmunityBio, Inc.
• KaliVir Immunotherapeutics
• Neonc Technologies, Inc.
• SystImmune Inc.
• Medicenna Therapeutics, Inc.
• Sensei Biotherapeutics, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)